Indeed, antibodies directed the immune checkpoints CTLA-4 (cytotoxic T lymphocyte-associated protein 4) and PD-1 (programmed cell death protein-1) were shown to prolong the survival of cancer patients suffering from metastatic cancers. This evidence concerns the gene CTLA4 and cancer.